COMMISSION IMPLEMENTING REGULATION (EU) 2018/660
of 26 April 2018
renewing the approval of the active substance bentazone in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
(Text with EEA relevance)
Article 1
Renewal of the approval of the active substance
Article 2
Amendments to Implementing Regulation (EU) No 540/2011
Article 3
Entry into force and date of application
ANNEX I
Common Name, Identification Numbers |
IUPAC Name |
Purity(1) |
Date of approval |
Expiration of approval |
Specific provisions |
||||||||
Bentazone CAS No 25057-89-0 CIPAC No 366 |
3-isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-one 2,2- dioxide |
≥ 960 g/kg 1,2-dichloroethane < 3 mg/kg |
1 June 2018 |
31 May 2025 |
For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on bentazone, and in particular Appendices I and II thereof, shall be taken into account. In their overall assessment Member States shall pay particular attention to:
Conditions of use shall include risk mitigation measures, where appropriate. The applicant shall submit by 1 February 2019 to the Commission, the Member States and the Authority confirmatory information as regards Level 2/3 tests as currently indicated in the OECD Conceptual Framework investigating the potential for endocrine-mediated effects of bentazone. |
ANNEX II
Number |
Common Name, Identification Numbers |
IUPAC Name |
Purity(1) |
Date of approval |
Expiration of approval |
Specific provisions |
||||||||
‘120 |
Bentazone CAS No 25057-89-0 CIPAC No 366 |
3-isopropyl-1H-2,1,3-benzothiadiazin-4(3H)-one 2,2- dioxide |
≥ 960 g/kg 1,2-dichloroethane < 3 mg/kg |
1 June 2018 |
31 May 2025 |
For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on bentazone, and in particular Appendices I and II thereof, shall be taken into account. In their overall assessment Member States shall pay particular attention to:
Conditions of use shall include risk mitigation measures where appropriate. The applicant shall submit by 1 February 2019 to the Commission, the Member States and the Authority confirmatory information as regards Level 2/3 tests as currently indicated in the OECD Conceptual Framework investigating the potential for endocrine-mediated effects of bentazone.’ |